Hypermethylation of the ALDH1A3 promoter in GBM patients is associated with a low expression of ALDH1A3 and a better prognosis [81]; the same seems to be true for non-muscle-invasive bladder cancer [42]. Here, ALDH1A3 is linked to glioblastoma.